Quick Answer
Voyager Therapeutics, Inc. reported Operating Income Loss of -$131.84 million for the year ending 2025.
- Voyager Therapeutics, Inc. showed a decrease of -58.3% in Operating Income Loss from 2024 to 2025.
- This data is from Voyager Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Voyager Therapeutics, Inc.'s Operating Income Loss has declined by 817.7%.
- Historical annual values: Fiscal year 2025: -$131.84 million | Fiscal year 2024: -$83.29 million | Fiscal year 2023: $122.01 million | Fiscal year 2022: -$50.84 million | Fiscal year 2021: -$73.62 million | Fiscal year 2020: $27.38 million | Fiscal year 2019: -$51.68 million | Fiscal year 2018: -$91.10 million | Fiscal year 2017: -$71.86 million | Fiscal year 2016: -$41.30 million | Fiscal year 2015: -$20.25 million | Fiscal year 2014: -$14.37 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: